Bioretec LtdCompany release31 October 2025 at 8.30 a.m. EET Bioretec announced on 27 October 2025 that it will adjust and restate its previously reported figures for H1/2025. The adjustment and restatement is related to the sales and distribution agreement with Tri-State Biologics (“TSB”), originally announced on 22 November 2024 (the “TSB Distribution Agreement”). The TSB […]

(NASDAQ:CRBP), NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock

Corbus Pharmaceuticals Announces Pricing of Public Offering GlobeNewswire October 31, 2025 NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price

BEIJING, Oct. 31, 2025 (GLOBE NEWSWIRE) — From October 27 to 29, 2025, the 2025 World Science and Technology Development Forum, themed “AI for Science and Development (AI4SD)“, was successfully held at the China Hall of Science and Technology in Beijing. As one of the key events during the “The International Month 2025: Openness, Cooperation,

2025WSTDF-Green Hâ‚‚ Forum Held at Beijing GlobeNewswire October 31, 2025 BEIJING, Oct. 31, 2025 (GLOBE NEWSWIRE) — From October 27 to 29, 2025, the 2025 World Science and Technology Development Forum, themed “AI for Science and Development (AI4SD)“, was successfully held at the China Hall of Science and Technology in Beijing. As one of the

(TSE:4565.T), Second API manufacturing facility added to ensure supply for patients with insomnia in Japan and for future demand across the Asia-Pacific region Expected to improve profitability through manufacturing cost reductions to advance toward the 2030 Vision Cost reductions anticipated to begin contributing during 2027 through to the end of 2028 Tokyo, Japan and Cambridge

Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ(R) 25 and 50 mg GlobeNewswire October 31, 2025 Second API manufacturing facility added to ensure supply for patients with insomnia in Japan and for future demand across the Asia-Pacific region Expected to improve profitability through manufacturing

(TSE:4565.T), Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2025. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented:

Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025 GlobeNewswire October 31, 2025 Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine

Schubert Jonckheer & Kolbe LLP is investigating a data breachthat led to unauthorized access to the sensitive information of 10,515,849 individuals affiliated with clients of Conduent Business Services, LLC (“Conduent”), a New Jersey-based company that provides a range of back-office services, including printing, mailing, document processing, payment integrity services, and other support services to government